ABC NEWS | May 2022
0
Patrys CEO and Managing Director, Dr James Campbell, is presenting at the 16th Bioshares Biotech Summit to be hosted in…
Quarterly Activities Report and 4C
Patrys has published its Quarterly Activities Report and 4C Quarterly Cash Flow Report. Highlights for this Quarter have included: Work…
Patrys strengthens executive team
Patrys today announced the appointment of Dr Rebecca Tunstall to the role of Vice President, Corporate Development. As a key…
New research: Scientists determine structure of a DNA damage ‘First Responder’ protein
Scientists at the Sloan Kettering Institute have debunked a 20-year guiding paradigm for how the 9-1-1 clamp – a protein…
VIDEO | Dr James Campbell on Proactive
Patrys CEO and MD, Dr James Campbell, was interviewed by Proactive’s Andrew Scott today to discuss the importance of the…
PAT-DX3 Cell Line Selected
Patrys today announced that it has now developed and optimised a stable cell line for production of our full-sized IgG…
ADC Deals Making Headlines
Late last year, Patrys announced new data from a preclinical study that demonstrated potential for using our deoxymab antibodies as…
Quarterly Activities Report and 4C
Patrys has today published its Quarterly Activities Report and 4C Quarterly Cash Flow Report. Standout achievements for this Quarter have…
R&D Tax Refund
Patrys has today confirmed a $1,188,581 Research and Development (R&D) Tax Incentive Refund for the 2020/2021 financial year. We greatly…
PAT-DX1 Engineering Update
Patrys has today announced the completion of the first engineering run for its lead asset PAT-DX1. The purification of PAT-DX1…